Hypercholesterolemia - Pipeline Review, Q1 2011

Global Markets Direct, March 2011, Pages: 58

Hypercholesterolemia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hypercholesterolemia - Pipeline Review, Q1 2011', provides an overview of the Hypercholesterolemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. 'Hypercholesterolemia - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypercholesterolemia.
- A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypercholesterolemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Hypercholesterolemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercholesterolemia
Hypercholesterolemia Therapeutics under Development by Companies
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hypercholesterolemia Therapeutics - Products under Development by Companies
Hypercholesterolemia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hypercholesterolemia Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Tekmira Pharmaceuticals Corp.
Merck & Co., Inc.
Novartis AG
MDRNA, Inc.
Santaris Pharma A/S
Aegerion Pharmaceuticals, Inc.
Karo Bio
Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc.
Obecure Ltd.
VIA Pharmaceuticals, Inc.
Relypsa, Inc.
Hypercholesterolemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Mipomersen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomitapide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin 40mg - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ezetrol + Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0653C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Crestor + Ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Pravastatin + Lifibrol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercholesterolemia Therapeutics - Discontinued Products
Hypercholesterolemia - Featured News
Oct 05, 2010: ACR Image Metrix Announces Publication Of Phase III Trial Abstract In Online Supplement Of therosclerosis
Sep 01, 2010: Genzyme And Isis Report Positive Data From Mipomersen Phase III Trial In heFH Patients
Aug 11, 2010: Karo Bio To Present Clinical Phase III Development Plan For Eprotirome For Treatment Of Heterozygous Familial Hypercholesterolemia
Aug 04, 2010: Genzyme And Isis Report Results Of Two Phase III Trials Of Mipomersen
Jul 07, 2010: Karo Bio To Initially Develop Eprotirome For Heterozygous Familial Hypercholesterolemia
Mar 30, 2010: marketed
Mar 25, 2010: jjjjjjjjjjjjjjjjjjjjjjjjjjjjb
Mar 16, 2010: Genzyme And Isis Announce Publication Of Mipomersen Phase III Study Data In The Lancet
Mar 14, 2010: ACC: Rosuvastatin and Ezetimibe Combo Tops LDL Trial
Feb 24, 2010: Tekmira Presents ApoB SNALP Data At AsiaTIDES RNAi Scientific Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypercholesterolemia, Q1 2011
Products under Development for Hypercholesterolemia – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Tekmira Pharmaceuticals Corp., 2011
Merck & Co., Inc., 2011
Novartis AG, 2011
MDRNA, Inc., 2011
Santaris Pharma A/S, 2011
Aegerion Pharmaceuticals, Inc., 2011
Karo Bio, 2011
Alnylam Pharmaceuticals, Inc, 2011
Regeneron Pharmaceuticals, Inc., 2011
Obecure Ltd., 2011
VIA Pharmaceuticals, Inc., 2011
Relypsa, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Hypercholesterolemia, Q1 2011
Products under Development for Hypercholesterolemia – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Discovery and Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Customers who bought this item also bought

• Nitric Oxide - Therapeutics, Markets and Companies
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Hypercholesterolemia Therapy Area Pipeline Report
• Brain Tumor – Pipeline Review, H1 2013
• Sleep Disorders – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Essential Thrombocythemia – Pipeline Review, H1 2013